10.06.2024 | Commentary
When millimeters matter
verfasst von:
Bhavya R. Shah
Erschienen in:
European Radiology
|
Ausgabe 8/2024
Einloggen, um Zugang zu erhalten
Excerpt
Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) has revitalized ablation as a treatment option for essential tremor (ET) and Parkinson’s disease (PD). For patients, focused ultrasound (FUS) represents an attractive, incision-less option that obviates the need for intra-cranial implants. For engineers, physicists, and physicians, MRgHIFU represents the evolution of a dream: that someday it would be possible to eloquently treat diseases of the brain without breaching the cranial vault. While ablative applications are FDA-approved for movement disorders, low-intensity focused ultrasound (LIFU) applications (e.g., temporary blood–brain barrier disruption, sonodynamic therapy, histotripsy, and neuromodulation) are in clinical trials [
1,
2]. …